Prof. Hubert Schrezenmeier

Further involvements

• 22/09/2022

  13:50 – 14:00 6 Min. 4 Min.

  • Abstractvortrag
  • VS-13-3

  Long-term Follow up (> 1 year) of Plasma Donors and Patients treated with COVID-19 Convalescent Plasma within the CAPSID trial

   19. COVID-19, 9. Hämotherapie
• 22/09/2022

  14:00 – 14:10 6 Min. 4 Min.

  • Abstractvortrag
  • VS-13-4

  A Randomised Open-Label Trial of Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19 as model of early treatment in a pandemia with a new pathogen: Experience from collection of very high-titer plasma from superimmunized individuals

   1. Blutspende und Donormanagement, 19. COVID-19
• 22/09/2022

  16:00 – 16:10 6 Min. 4 Min.

  • Abstractvortrag
  • VS-16-2

  Higher risk for chronic graft-versus-host disease (GvHD) in HLA-G mismatched transplants following allogeneic hematopoietic stem cell transplantation (allo-HSCT)

   8. Immungenetik: HLA und Transplantationen
• 22/09/2022

  17:00 – 17:05 3 Min. 2 Min.

  • Poster
  • PS-5-9

  Detection of SARS-CoV-2 Spike-Protein-Specific Antibodies after Vaccination via Nasal and Buccal Swabs: Prospects for Mass Scale Immunity-Screening in Large Populations

   19. COVID-19
• 22/09/2022

  17:25 – 17:30 3 Min. 2 Min.

  • Poster
  • PS-4-14

  Ex-vivo expansion of autologous bone marrow-derived mesenchymal stromal cells for treatment of bone defects: Impact of donors characteristics and quality of starting material of efficacy of expansion

   12. Zelltherapie und Gentherapie, 18. Zukunftsgebiete der Transfusionsmedizin
• 22/09/2022

  17:40 – 17:45 3 Min. 2 Min.

  • Poster
  • PS-5-17

  BNT162b2 booster vaccination elicits cross-reactive immunity against SARS-CoV-2 variants B.1.1.529 and B.1.617.2 in convalescents of all ages

   18. Zukunftsgebiete der Transfusionsmedizin, 19. COVID-19
• 23/09/2022

  09:30 – 09:40 6 Min. 4 Min.

  • Abstractvortrag
  • VS-19-5

  Phase I clinical trial on hematopoietic stem cell recipients transfused with FFP from donors with highly potent anti-CMV antibodies

   13. Neue Blutprodukte – Neue Anwendungen, 18. Zukunftsgebiete der Transfusionsmedizin
• 23/09/2022

  09:50 – 10:00 6 Min. 4 Min.

  • Abstractvortrag
  • VS-21-9

  Upregulation of check-point ligand PD-L1 in patients with PNH explained by proximal complement activation

   7. Immunhämatologie und Immunologische Grundlagen, 9. Hämotherapie